About this trial
The goal of this clinical trial is to determine the relative efficacy of fMRI model guided Transcranial Direct Current Stimulation (mgTDCS) in improving the depressive symptoms of patients with Parkinson's Disease (PD). The main questions it aims to answer are: 1) Can the use of mgTDCS significantly improve the self-reported level of depression and apathy in patients with PD from pre-intervention to post-intervention compared to a sham control? 2) Can the use of mgTDCS significantly normalize the cortical eeg alpha asymmetry so commonly seen in depressed patients compared to sham mgTDCS? 3) Can the use of mgTDCS significantly improve scores on neuropsychological tests of working memory?
Eligibility criteria
Qualifiers
19 to 65 years in age.
Parkinson's Group must have a physician dx of Parkinson's Disease
Must meet exhibit elevated levels of depression on the Beck Depression Inventory (scores of 20 or above).
Must be willing and able to travel of the Psychology Department for EEG and tDCS sessions.
Disqualifiers
No history of or being treated for epilepsy or other seizure disorders.
No history of penetrating head wounds or TBI greater than mild TBI.
No history of atypical Parkinson's
Trial design
Treatments tested in this trial
- BIOPAC Stimsola
- BIOPAC Stimsola Sham (zero amps)